Artificial intelligence-generated synthetic data for cancer research and clinical trials

Comprehensive Summary

Eckardt et al. discuss how artificial intelligence models such as generative adversarial networks (GANs), diffusion models, and large language models can create realistic sets of data that mimic real cancer data. This can include images, genomic profiles, and clinical records. The synthetic data produced by these artificial intelligence models can help address limitations in oncology research, such as small sample size, privacy constraints, and underrepresentation of rare cancers/demographic groups. By altering already existing datasets, the synthetic data can improve model training and enable safer data training without the risk of exposing patient information. Eckardt et al. also note risks of bias amplification, data leaks, and insufficient realism that need to be validated to ensure synthetic data fully represents biological and clinical variability.

Outcomes and Implications

Artificial intelligence-generated data has the power to accelerate cancer research and modernize clinical trials by making large, diverse, and privacy-preserving datasets more accessible. This suggests better predictive models, trial design, and development of therapies as outcomes. Eckardt et al. stress that synthetic data should complement and not replace real patient data, meaning artificial intelligence-created data needs to be validated, regulated, and transparently reported in order for the most accurate conclusions. This work suggests that the responsible integration of synthetic data into oncology research has the potential to improve reproducibility and equity in clinical research, as long as the synthetic data has been validated.